

FDA

U.S. FOOD & DRUG  
ADMINISTRATION

CENTER FOR DEVICES & RADIOLOGICAL HEALTH

FDA

# CDRH

## Virtual Town Hall Meeting

*For developers of tests for SARS-CoV-2*

Timothy Stenzel, MD, PhD and Toby Lowe  
Center for Devices and Radiological Health  
February 10, 2021

# Federal funding opportunity: Solicitation for Area of Interest (Aol)

## Aol-0003 FA811921SC001:

### SUPPLY CHAIN COVID-19 DIAGNOSTIC TESTING



**Capacity expansion investment funding** for vendors that have developed or are developing products relevant to COVID-19 diagnostic tests

**Supply chain materials and equipment in scope** (see Aol for all)

- Sample collection and testing consumables
- Raw materials, components, processes supporting diagnostics tests, kits/cartridges and related instruments
- Equipment to expand manufacturing capacity and/or increase test throughput
- Manufacturing and equipment related to temperature sensitive diagnostic testing, including their distribution and storage

#### Some Limitations

- Does not include distributors
- Manufacturing expansion limited to domestic or within US territories, although manufacturers may be foreign-owned

#### See Aol for solution brief contents

- Product description, diagnostic activity supported, technology
- Ability to ramp up production, other operational and commercial considerations
- Total proposal cost/price (requested investment, per item price quotes)

**Funding:** Coordinated between HHS/OASH and DoD to meet HHS COVID-19 response priorities

**Aol Open Period:** Closes 4:00PM CST March 7, 2021

**Aol Link:**

<https://beta.sam.gov/opp/477a27c88b634668bee5aa33532bee62/view>

#### **DAF ACT Commercial Solutions Opening (CSO) COVID-19 Response**

Click blue “View Changes” button, scroll to Attachments/Links for document dated Feb 05, 2021

#### **General Information**

[View Changes](#)



44 KB

Public

Feb 05, 2021

[Aol-0003\\_FA811921SC001-Supply](#)

[Chain COVID-19 Diagnostic Testing](#)

[\\_Final.docx](#)

**Any questions:**

[supplychain.cso.dafact@afwerx.af.mil](mailto:supplychain.cso.dafact@afwerx.af.mil)

# Resources for COVID-19 Test Development and Validation



- To sign up to receive emails on this CDRH topic, please subscribe to the **In Vitro Diagnostics Mailing List**: <https://www.fda.gov/about-fda/center-devices-and-radiological-health/subscribe-cdrh-mailing-lists>
- Questions about COVID-19 IVD EUAs: [CDRH-EUA-Templates@fda.hhs.gov](mailto:CDRH-EUA-Templates@fda.hhs.gov)
- Questions about laboratory data harmonization for COVID-19 testing: [SHIELD-LabCodes@fda.hhs.gov](mailto:SHIELD-LabCodes@fda.hhs.gov)
- *In Vitro* Diagnostics EUAs webpage: <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas>
- FAQs on COVID-19 Testing: <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-testing-sars-cov-2>
- Serology Testing Performance: <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance>
- Independent Evaluations of COVID-19 Serological Tests <https://open.fda.gov/apis/device/covid19serology/>
- January 2021 HHS FAQ: COVID-19 Diagnostic Data Standards & Core Data Elements for Test Reporting:  
<https://www.hhs.gov/sites/default/files/hhs-diagnostic-data-faqs.pdf>
- HHS COVID-19 Testing and Diagnostics Working Group (TDWG): Additional Testing Information:  
<https://www.hhs.gov/coronavirus/testing/testing-diagnostics-working-group/index.html>

## Publications:

- [https://www.nejm.org/doi/full/10.1056/NEJMp2023830?query=featured\\_home](https://www.nejm.org/doi/full/10.1056/NEJMp2023830?query=featured_home)
- <https://thehill.com/opinion/healthcare/515628-fda-were-constantly-working-on-covid-testing-options>

Transcript and Webinar Recording will be available at:

<http://www.fda.gov/training/cdrhlearn>

*Under Heading: Specialty Technical Topics; Subheading: In Vitro Diagnostics*

Please complete a short survey about your FDA CDRH webinar experience. The survey can be found at:

[www.fda.gov/cdrhwebinar](http://www.fda.gov/cdrhwebinar)

immediately following the conclusion of the live webinar